CAR T cell therapy has transformed the treatment of B cell cancers and is now being pursued by biotech companies for conditions as varied as systemic lupus erythematosus, diabetes and organ rejection.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kansal, R. et al. Sci. Transl. Med. 11, eaav1648 (2019).
Mougiakakos, D. et al. New Engl. J. Med. 385, 567–569 (2021).
Mackensen, A. et al. Nat. Med. 28, 2124–2132 (2022).
Klatzmann, D. et al. Science 225, 59–63 (1984).
Harrison, A. J., Du, X., von Scheidt, B., Kershaw, M. H. & Slaney, C. L. Immunother. Adv. 1, ltab016 (2021).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Arnold, C. Autoimmune disease is the next frontier for CAR T cell therapy. Nat Med 30, 6–9 (2024). https://doi.org/10.1038/s41591-023-02716-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-023-02716-7
